CA1191856A - Process for preparing optically active imidazolylpropanol compounds, and intermediate therein - Google Patents
Process for preparing optically active imidazolylpropanol compounds, and intermediate thereinInfo
- Publication number
- CA1191856A CA1191856A CA000428760A CA428760A CA1191856A CA 1191856 A CA1191856 A CA 1191856A CA 000428760 A CA000428760 A CA 000428760A CA 428760 A CA428760 A CA 428760A CA 1191856 A CA1191856 A CA 1191856A
- Authority
- CA
- Canada
- Prior art keywords
- formula
- optically active
- acid
- compounds
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
PROCESS FOR PREPARING OPTICALLY ACTIVE IMIDAZOLYLPROPANOL
COMPOUNDS, AND INTERMEDIATE THEREIN
An optically active imidazolylpropanol compound of the formula:
(I) wherein n is an integer of 3 or 4, and its acid addition salts, which is useful as an antifungal agent, prepared by reacting an imidazolylthiol of the formula:
(II) with an alkylating agent of the formula:
CH3-(CH2)n-X (III) whrein n is as defined above and X is a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group.
PROCESS FOR PREPARING OPTICALLY ACTIVE IMIDAZOLYLPROPANOL
COMPOUNDS, AND INTERMEDIATE THEREIN
An optically active imidazolylpropanol compound of the formula:
(I) wherein n is an integer of 3 or 4, and its acid addition salts, which is useful as an antifungal agent, prepared by reacting an imidazolylthiol of the formula:
(II) with an alkylating agent of the formula:
CH3-(CH2)n-X (III) whrein n is as defined above and X is a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group.
Description
PROCESS FOR PREPARING OPTICALLY ACTIVE IMIDAZOLYLPROPANOL
_ CO~IPOUNDS, AND INTERMEDIATE THEREIN
. . _ .
The present invention relates to a process for preparing optically active imidazolylpropanol compounds, and an intermediate therein.
The said optically active imidazolylpropanol compounds are representable by the formula:
~N
N
C 2 ~ CH2-S-(CH2)n CH3 C ~ '-OH (I) Cl wherein n is an integer of 3 or 4.
The racemic mixture of an imidazolylpropanol compound corresponding to the formula (I) is known to be useful as an antifungal agent (cf. Japanese Patent Publication (unexamined) No. 106666/1982). In order to provide more active compounds, an extensive study has been made, and it ha~ been found that the (R)-isomer o the imidazolylpropanol compound (I) is highly active.
On Candida infection in mice, the said (R)-isomer showed a more remarkable effect in decreasing mortality than the corresponding racemate or (S)-isomer. Thus, the (R)-lsomer is particularly useful as an antifungal agent.
..
5~
The present invention provides a novel process for preparing the optically active imidazolylpropanol compounds of the formula tI), i.e. the ~R)-isomer, which may be illustratively shown in the following scheme:
~;~
o 1H 2~
,~Cl Cl (racemic) (I~) HS~ ~ Cl (V) I
- [~ y ~ O ~
CH2` ~ CH2-S-C ~ Cl ~ CH2 ~ CH2-S-C /S ~ Cl 110 -- ~ Cl Cl ~OH
C
(VIa) (VIb) ~9~jl5~
(VIb ) ~N ~ -
_ CO~IPOUNDS, AND INTERMEDIATE THEREIN
. . _ .
The present invention relates to a process for preparing optically active imidazolylpropanol compounds, and an intermediate therein.
The said optically active imidazolylpropanol compounds are representable by the formula:
~N
N
C 2 ~ CH2-S-(CH2)n CH3 C ~ '-OH (I) Cl wherein n is an integer of 3 or 4.
The racemic mixture of an imidazolylpropanol compound corresponding to the formula (I) is known to be useful as an antifungal agent (cf. Japanese Patent Publication (unexamined) No. 106666/1982). In order to provide more active compounds, an extensive study has been made, and it ha~ been found that the (R)-isomer o the imidazolylpropanol compound (I) is highly active.
On Candida infection in mice, the said (R)-isomer showed a more remarkable effect in decreasing mortality than the corresponding racemate or (S)-isomer. Thus, the (R)-lsomer is particularly useful as an antifungal agent.
..
5~
The present invention provides a novel process for preparing the optically active imidazolylpropanol compounds of the formula tI), i.e. the ~R)-isomer, which may be illustratively shown in the following scheme:
~;~
o 1H 2~
,~Cl Cl (racemic) (I~) HS~ ~ Cl (V) I
- [~ y ~ O ~
CH2` ~ CH2-S-C ~ Cl ~ CH2 ~ CH2-S-C /S ~ Cl 110 -- ~ Cl Cl ~OH
C
(VIa) (VIb) ~9~jl5~
(VIb ) ~N ~ -
2 ~ 2 C l~f ' OH
Cl (II) .
CH3- (CH2~ n~X
(III) ~ /
(I).
In the above method, the racemic epoxide of the formul.a (IV) is irst reacted with an optically active thiolccarboxylic acid of the formula (V) in an inert solvent at a température of from about -20 to 80C to give a 1:1 diastereomeric mixture of the thioloes~ers (VIa) and (VIb).
The racemic epoxide (VI) is known (cf. Japanese Patent Publications (unexamined~ Nos. 12372/1981 and 106666/1982). The optically active thiolocarboxylic acid (V) ca:n be prepared from the corresponding carhoxylic acid chloride of the formula:
5~
O ~ ,H
Cl-ll~Cl (J.Synthetic Organic Chemistry, Japan, 38, 1151-1162 (1980)) by reacting the latter with potassium or sodium hydrosulfide in an inert solvent such as a hydrocarbon (e.g. benzene, toluene) or an alcohol (e.g. methanol, ethanol~ at a temperature of about -10 to 10C (cf. Org. Synthesis, Col.
Vol. III, p. 116). The optically active thiolocarboxylic acid ~V) is merely a typical example, and other optically active thiolocarboxylic acids such as (~ methoxy-~-tri-fluoromethylphenyl~hioloacetic acid and L-menthoxythiolo-ace~ic acid may be also used. These optically active thiolocarboxylic acids are representable by the formula:
A-SH wherein A is an optically active acyl gxoup. Examples of the inert solvent are hydrocarbons (e.g. n-hexane, benzene, xylene~, alcohols ~e.g. methanol, ethanol, isopropanol), halogenated hydrocarbons (e.~. dichloro-methane, chloroform, 1,2-dichloroethane), ketones (e.g~
acetone, methyl ethyl ketone), ethers (e.g. diethyl ether, t~trahydrofuran, dioxane), esters (e.g. ethyl ac tate), amides (e.g. N,N-dimethylformamide, N,N-dimethylacetamide), etc. The amount of the optically active thiolocarboxylic acid (V) may be usually a molar equivalent or slightly excess to the racemic epoxide (IV).
From the 1:1 diastereomeric mixture, the (R)-isomer (VIb) is separa$ed and collected by a per se conventional separation procedure such as fractional crystallization. For the fractional crystallization, an inert solvent such as an alcohol (e.g. methanol, ethanol, isopropanol) or a hydrocarbon (e.g. n-hexane, b~nzene, toluene, xylene) may be used.
The most straightforward procedure for obtaining the desired (R)-isomer (VIb) comprises performing the reaction between the racemic epoxide (IV) and the op-tically active thiolocarboxylic acid (V) in a solvent usable for the fractional crystallization. In such case, the crystals of the (R)-isomer are separated out from the reaction system on the completion of the reaction and can be readily collected by filtration.
The separated (R)-isomer (VIb) is then treated with a base in an inert solvent at a temperature of about -lO to 100C in an inert atmosphere (e.g. nitrogen, argon) to give the imidazolylthiol of the formula (II). As the base, there may be used an alkali metal hydroxide (e.g.
lithium hydroxide, sodium hydroxide, potassium hydroxide), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal alcoholate (e.g. sodium ethylate, sodium methylate), an alkali metal sulfhydrate (e.g. sodium sulfhydrate, potassium sulfhydrate), ammonia, organic amines (e.g. monomethylamine, diethylamine, triethylamine), etc. Examples of the inert solvent are water, alcohols (e.g. methanol, ethanol, isopropanol), ketones (e.g. acetone, methyl ethyl ketone), ethers (diethyl B5~
ether, tetrah~drofuran~ dioxane), amides (e.g. N,N-dimethyl-formamide, N,N-dimethylacetamide), etc. Their mixtures are also usable. The amount of the base is usually not less than l mole, preferably from 1 to 20 moles, per mole of the (~)-isomer (VIb).
Then, the imidazolylthiol (II) is reacted with an alkylating agent of the formula (III), preferably in the presence of a base in an inert solvent to give the objective optically active imidazolylpropanol compound (I). In the formula (III) for the alkylating agent, X represents a halogen atom (e.gO chlorine, bromine, iodine), an alkyl-sulfonyloxy group le.g. methanesulfonylo~y) or an aryl-sulfonyloxy group (e.g. benzenesulfonyloxy, toluene-sulfonyloxy). Examples of the base are an alkali metal hydroxide (e.g. lithium hydroxide, sodium hydroxide, potassium hydroxide), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal (e.g.
lithium, sodium, potassium), an alkali metal hydride (e.g.
sodium hydride), a tertiary amine (e.g. pyridine, triethylamine), etc. As the inert solvent, there may be used a hydrocarbon (e.g. benzene, toluene, xylene), a chlorinated hydrocarbon (e.g. methylene chloride, chloro-form, 1,2-dichloroethane), an alcohol (e.g. methanol, ethanol, isopropanol), a ketone (e.g. acetone, methyl ethyl ketone), an ether (e.g. diethyl ether, tetrahydrofuran, dio~.ane), an ester (e.g. ethyl acetate), an amide (e.g. N,N-dimethylformamide, N,N-dimethylacetamide), water, etc. The 35~
amount of the alkylating agent (III) may be more than 1 mole, preferably 1 to 10 moles, per mole of the imidazolyl-thiol (II). The amount of the base is usually more than 1 mole, preferably 1 to 30 moles, per mole of the imidazolyl-thiol (II). The rèaction temperature is usual:Ly above -20C, preferably from -20 to 100C.
The optically active imidazolylpropanol compound (I) can be prepared more conveniently and advantageously by treating the (R)-isomer (VIb) successively with -the base and with the alkylating agent (III~ in a single reaction vessel without isolation of the intermediarily produced imidazolyl-thiol (II).
The manner for recovery of the optically active imidazolylpropanol compound (I) from the reaction mixture depends upon the property of the reac-tants as used, but in general, the reaction mixture is subjected to evaporation of the solvent, dilution of the residue with water and extrac-tion of the objective optically active imidazolylpropanol compound (I) with an appropriate water-immiscible solvent.
The thus produced optically active imidazolyl-propanol compound (I) may be converted into its acid add.ition salt by treatment with an acid (e.g. hydrochloric acid t hydrobromic acid, phosphoric acid, nitric acid, acetic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid, lactic acid, oxaLic acid).
The optically active imidazolylpropanol compounds of the formula (I) are usually administered to pa-tients orally or parenterally and are ordinarily employed in the form of a pharmaceutical composition which contains them in an effective and non-toxic amount in admixture with conventional pharmaceutical carrier materials suitable for oral or parenteral application and being unreactive with the active compounds. The pharmaceutical composition may be in the dosage form of tablets, capsules, granules, fine granules, powders, syrups, suspensions, emulsions, supposi-tories, injections, or the like. These pharmaceutical compositions can be prepared by conventional methods by us:ing conventional carrier materials, excipients, binding agents, stabilizers, etc. For injection, the preparation may be prepared by dissolving the active compounds in purified water for injection, which may optionally contain other additives, such as isotonic agen-ts (e.g. glucose, saline~, buffexing agents, solubilizers, pH adjusting agents or preservatives.
The dosage of the optically active imidazolyl-propanol compounds (I) may vary with the administration rou~es, the age and weight of the patient, the kinds and severity of the diseases to be treated, or the like. In case of oral administration in adult, it is usually used in an amount of 50 to 1,000 mg, preferably of 100 to 500 mg, ~er day, which may be administered once a day but may also be divided and administered in two to several times per day.
In case of injection in adult, it is usually used in an amount of 10 to 400 mg, preferably 20 to 200 mg, per day, ~hlch may be administered once a day but may also be divided and administered in two to several times per clay.
Practical and presently preferred embodiments for production of the compounds (I) are illustratively shown in the following Examples.
Example 1 .
Preparation of (R)-3-[(S)-2-(4-chlorophenyl)iso-valerylthio]-2-(2,4-dichlorophenyl)-1-(imidazol-1-yl)-2-propanol (VIb)o-To a solution of dl-2-(2,4-dichlorophenyl)-2-(imidazol-l-yl)methyloxirane (IV) (269 y) in toluene (1100 ml) was added (S)-2-(4-chlorophenyl)thioloisovaleric acid (V) (229 g) obtained in Reference Example 5 at room temperature. The mixture was stirred without external cooling, while the temperature raised spontaneously to 55C
during the first 10 minutes. The mixture was kept at the same temperarture as above for another 1 hour and then at 20C for 3 hours. The precipitate was collected by filtration, washed successively with toluene and isopropanol and dried in vacuo to give (R)-3-[(S)-2-(4-chlorophenyl)iso valerylthio]-2-(2,4-dichlorophenyl)-1-(imidazol-1 yl)-2~
propanol (VIb) (204 g). Yield, 41 ~. M.P., 182 - 183C.
[a]23 -1.0 (c = 1, methanol).
Example 2 Preparation of (R)-2-(2j4-dichlorophenyl)-1-(imidazol-l-yl)-3-mercapto-2-propanol (II):-~3~
To a suspension o~ the compound (VIb~ [49.5 g)obtained in Example 1 in toluene (300 ml) was added a 10 %
me-thanolic potassium hydroxide solution (160 g) at a temperature of -5C to 0C in nitrogen atmosphere. The mixture was warmed to 25C over a peîiod of about 30 minutes and stirred at the same temperature for 2 hours. The reaction mixture was concentrated under reduced pressure.
The residue was dissolved ln dichloromethane (300 ml), washed with water, dried and evaporated to give an oil. The oil was purified by silica gel column chromatography using chloroform as an eluent and recrystallized from a mixture of dichloromethane and n-he~ane to give (R)-2-(2,4-dichloro-phenyl)-1-(imidazol-1-yl)-3-mercapto-2-propanol (II) t9.4 g). Yield, 31 %. M.P., 155 - 157C. [~]D -6.6 (c = 1, methanol).
Example 3 Preparation of (R)-2-(2,4-dichlorophenyl)-1-(imidazol-l-yl)-3-mercapto-2-propanol (II):-~ In the same manner as in Example 2 but using 10 %
water-containing methanol (400 ml~ and sodium sulfhydrate (10 g) in place of methanol and potassium hydroxide, respectively, there was obtained (R)-2-(2,4-dichlorophenyl)-l-(imidazol-l-yl~-3-mercapt~-2-propanol (II) (11.3 g).
Yield, 37 %. M.P., 156 - 157C. [~]D4 ~7 0 (c = 1, methanol).
Example 4 - l l -Preparation of (R)-3-(n-butylthio)--2-(2,4-di-chlorophenyl)-l-(imidazol l-yl)-2-propanol (I: n = 3) hydrochloride:-To a solution of sodium hydro~ide (2 ~) inmethanol (100 ml) were added n-butylbromide (2 g) and (~)-2-(2,4-dichlorophenyl)-1-(imidazol-1-yl)-3-mercapto-2-propanol (II) obtained in Example 2 at a temperature of 20 - 25C in nitrogen atmosphere. The mixture was stirred at 25 - 30C
for 5 hours and then concentrated under reduced pressure.
The residue was treated with water (50 ml) and extracted with dichloromethane (50 ml). The extract was washed with water, dried over anhydrous magnesium sulfate and concen-trated to give an oil. The oil was dissolved in diethyl ether (20 ml), and hydrogen chloride gas was introduced thereto. Precipitated crystals were collected by filtration and dried to give (R)-3-(n-butylthio)-2~(2,4-dichloro-phenyl)-1-(imidazol-1-yl)-2-propanol (I: n = 3) hydro-chloride (3.4 g). Yield, 86.8 %. M.P., 168 - 169C. [~]20 -89.7 (c = 1, methanol). The optical purity of the product was not less than 99 % determined by high performance liquid chromatography.
Example 5 Preparation of ~R)-3-(n-butylthio)-2-(2,4-di-chlorophenyl) l-(imida~ol-l-yl)-2-propanol (I: n = 3) hydrochloride:-T~ a solution of (R)-2-(2,4-dichlorophenyl)-1-limidazol-l-yl)-3-mercapto-2-propanol (II) t3 g) in dxy N,N-dimeth~lformamide (20 ml) were added a 50 ~ dispersion of sodium hydride iII paraffin (1 g) and n-butyl p-toluene-sulfonate (2.3 g) at 0 - 5C in nitroclen atmosphere. The rnixture was stirred at 0 - 5C for 1 hour and at 20 - 25C
for 18 hours. The reactlon mixture was diluted wi-th water (200 ml) and extracted with dichloromethane. Treatment of the extract in the same manner as in Example 4 gave (R)-
Cl (II) .
CH3- (CH2~ n~X
(III) ~ /
(I).
In the above method, the racemic epoxide of the formul.a (IV) is irst reacted with an optically active thiolccarboxylic acid of the formula (V) in an inert solvent at a température of from about -20 to 80C to give a 1:1 diastereomeric mixture of the thioloes~ers (VIa) and (VIb).
The racemic epoxide (VI) is known (cf. Japanese Patent Publications (unexamined~ Nos. 12372/1981 and 106666/1982). The optically active thiolocarboxylic acid (V) ca:n be prepared from the corresponding carhoxylic acid chloride of the formula:
5~
O ~ ,H
Cl-ll~Cl (J.Synthetic Organic Chemistry, Japan, 38, 1151-1162 (1980)) by reacting the latter with potassium or sodium hydrosulfide in an inert solvent such as a hydrocarbon (e.g. benzene, toluene) or an alcohol (e.g. methanol, ethanol~ at a temperature of about -10 to 10C (cf. Org. Synthesis, Col.
Vol. III, p. 116). The optically active thiolocarboxylic acid ~V) is merely a typical example, and other optically active thiolocarboxylic acids such as (~ methoxy-~-tri-fluoromethylphenyl~hioloacetic acid and L-menthoxythiolo-ace~ic acid may be also used. These optically active thiolocarboxylic acids are representable by the formula:
A-SH wherein A is an optically active acyl gxoup. Examples of the inert solvent are hydrocarbons (e.g. n-hexane, benzene, xylene~, alcohols ~e.g. methanol, ethanol, isopropanol), halogenated hydrocarbons (e.~. dichloro-methane, chloroform, 1,2-dichloroethane), ketones (e.g~
acetone, methyl ethyl ketone), ethers (e.g. diethyl ether, t~trahydrofuran, dioxane), esters (e.g. ethyl ac tate), amides (e.g. N,N-dimethylformamide, N,N-dimethylacetamide), etc. The amount of the optically active thiolocarboxylic acid (V) may be usually a molar equivalent or slightly excess to the racemic epoxide (IV).
From the 1:1 diastereomeric mixture, the (R)-isomer (VIb) is separa$ed and collected by a per se conventional separation procedure such as fractional crystallization. For the fractional crystallization, an inert solvent such as an alcohol (e.g. methanol, ethanol, isopropanol) or a hydrocarbon (e.g. n-hexane, b~nzene, toluene, xylene) may be used.
The most straightforward procedure for obtaining the desired (R)-isomer (VIb) comprises performing the reaction between the racemic epoxide (IV) and the op-tically active thiolocarboxylic acid (V) in a solvent usable for the fractional crystallization. In such case, the crystals of the (R)-isomer are separated out from the reaction system on the completion of the reaction and can be readily collected by filtration.
The separated (R)-isomer (VIb) is then treated with a base in an inert solvent at a temperature of about -lO to 100C in an inert atmosphere (e.g. nitrogen, argon) to give the imidazolylthiol of the formula (II). As the base, there may be used an alkali metal hydroxide (e.g.
lithium hydroxide, sodium hydroxide, potassium hydroxide), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal alcoholate (e.g. sodium ethylate, sodium methylate), an alkali metal sulfhydrate (e.g. sodium sulfhydrate, potassium sulfhydrate), ammonia, organic amines (e.g. monomethylamine, diethylamine, triethylamine), etc. Examples of the inert solvent are water, alcohols (e.g. methanol, ethanol, isopropanol), ketones (e.g. acetone, methyl ethyl ketone), ethers (diethyl B5~
ether, tetrah~drofuran~ dioxane), amides (e.g. N,N-dimethyl-formamide, N,N-dimethylacetamide), etc. Their mixtures are also usable. The amount of the base is usually not less than l mole, preferably from 1 to 20 moles, per mole of the (~)-isomer (VIb).
Then, the imidazolylthiol (II) is reacted with an alkylating agent of the formula (III), preferably in the presence of a base in an inert solvent to give the objective optically active imidazolylpropanol compound (I). In the formula (III) for the alkylating agent, X represents a halogen atom (e.gO chlorine, bromine, iodine), an alkyl-sulfonyloxy group le.g. methanesulfonylo~y) or an aryl-sulfonyloxy group (e.g. benzenesulfonyloxy, toluene-sulfonyloxy). Examples of the base are an alkali metal hydroxide (e.g. lithium hydroxide, sodium hydroxide, potassium hydroxide), an alkali metal carbonate (e.g. sodium carbonate, potassium carbonate), an alkali metal (e.g.
lithium, sodium, potassium), an alkali metal hydride (e.g.
sodium hydride), a tertiary amine (e.g. pyridine, triethylamine), etc. As the inert solvent, there may be used a hydrocarbon (e.g. benzene, toluene, xylene), a chlorinated hydrocarbon (e.g. methylene chloride, chloro-form, 1,2-dichloroethane), an alcohol (e.g. methanol, ethanol, isopropanol), a ketone (e.g. acetone, methyl ethyl ketone), an ether (e.g. diethyl ether, tetrahydrofuran, dio~.ane), an ester (e.g. ethyl acetate), an amide (e.g. N,N-dimethylformamide, N,N-dimethylacetamide), water, etc. The 35~
amount of the alkylating agent (III) may be more than 1 mole, preferably 1 to 10 moles, per mole of the imidazolyl-thiol (II). The amount of the base is usually more than 1 mole, preferably 1 to 30 moles, per mole of the imidazolyl-thiol (II). The rèaction temperature is usual:Ly above -20C, preferably from -20 to 100C.
The optically active imidazolylpropanol compound (I) can be prepared more conveniently and advantageously by treating the (R)-isomer (VIb) successively with -the base and with the alkylating agent (III~ in a single reaction vessel without isolation of the intermediarily produced imidazolyl-thiol (II).
The manner for recovery of the optically active imidazolylpropanol compound (I) from the reaction mixture depends upon the property of the reac-tants as used, but in general, the reaction mixture is subjected to evaporation of the solvent, dilution of the residue with water and extrac-tion of the objective optically active imidazolylpropanol compound (I) with an appropriate water-immiscible solvent.
The thus produced optically active imidazolyl-propanol compound (I) may be converted into its acid add.ition salt by treatment with an acid (e.g. hydrochloric acid t hydrobromic acid, phosphoric acid, nitric acid, acetic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid, lactic acid, oxaLic acid).
The optically active imidazolylpropanol compounds of the formula (I) are usually administered to pa-tients orally or parenterally and are ordinarily employed in the form of a pharmaceutical composition which contains them in an effective and non-toxic amount in admixture with conventional pharmaceutical carrier materials suitable for oral or parenteral application and being unreactive with the active compounds. The pharmaceutical composition may be in the dosage form of tablets, capsules, granules, fine granules, powders, syrups, suspensions, emulsions, supposi-tories, injections, or the like. These pharmaceutical compositions can be prepared by conventional methods by us:ing conventional carrier materials, excipients, binding agents, stabilizers, etc. For injection, the preparation may be prepared by dissolving the active compounds in purified water for injection, which may optionally contain other additives, such as isotonic agen-ts (e.g. glucose, saline~, buffexing agents, solubilizers, pH adjusting agents or preservatives.
The dosage of the optically active imidazolyl-propanol compounds (I) may vary with the administration rou~es, the age and weight of the patient, the kinds and severity of the diseases to be treated, or the like. In case of oral administration in adult, it is usually used in an amount of 50 to 1,000 mg, preferably of 100 to 500 mg, ~er day, which may be administered once a day but may also be divided and administered in two to several times per day.
In case of injection in adult, it is usually used in an amount of 10 to 400 mg, preferably 20 to 200 mg, per day, ~hlch may be administered once a day but may also be divided and administered in two to several times per clay.
Practical and presently preferred embodiments for production of the compounds (I) are illustratively shown in the following Examples.
Example 1 .
Preparation of (R)-3-[(S)-2-(4-chlorophenyl)iso-valerylthio]-2-(2,4-dichlorophenyl)-1-(imidazol-1-yl)-2-propanol (VIb)o-To a solution of dl-2-(2,4-dichlorophenyl)-2-(imidazol-l-yl)methyloxirane (IV) (269 y) in toluene (1100 ml) was added (S)-2-(4-chlorophenyl)thioloisovaleric acid (V) (229 g) obtained in Reference Example 5 at room temperature. The mixture was stirred without external cooling, while the temperature raised spontaneously to 55C
during the first 10 minutes. The mixture was kept at the same temperarture as above for another 1 hour and then at 20C for 3 hours. The precipitate was collected by filtration, washed successively with toluene and isopropanol and dried in vacuo to give (R)-3-[(S)-2-(4-chlorophenyl)iso valerylthio]-2-(2,4-dichlorophenyl)-1-(imidazol-1 yl)-2~
propanol (VIb) (204 g). Yield, 41 ~. M.P., 182 - 183C.
[a]23 -1.0 (c = 1, methanol).
Example 2 Preparation of (R)-2-(2j4-dichlorophenyl)-1-(imidazol-l-yl)-3-mercapto-2-propanol (II):-~3~
To a suspension o~ the compound (VIb~ [49.5 g)obtained in Example 1 in toluene (300 ml) was added a 10 %
me-thanolic potassium hydroxide solution (160 g) at a temperature of -5C to 0C in nitrogen atmosphere. The mixture was warmed to 25C over a peîiod of about 30 minutes and stirred at the same temperature for 2 hours. The reaction mixture was concentrated under reduced pressure.
The residue was dissolved ln dichloromethane (300 ml), washed with water, dried and evaporated to give an oil. The oil was purified by silica gel column chromatography using chloroform as an eluent and recrystallized from a mixture of dichloromethane and n-he~ane to give (R)-2-(2,4-dichloro-phenyl)-1-(imidazol-1-yl)-3-mercapto-2-propanol (II) t9.4 g). Yield, 31 %. M.P., 155 - 157C. [~]D -6.6 (c = 1, methanol).
Example 3 Preparation of (R)-2-(2,4-dichlorophenyl)-1-(imidazol-l-yl)-3-mercapto-2-propanol (II):-~ In the same manner as in Example 2 but using 10 %
water-containing methanol (400 ml~ and sodium sulfhydrate (10 g) in place of methanol and potassium hydroxide, respectively, there was obtained (R)-2-(2,4-dichlorophenyl)-l-(imidazol-l-yl~-3-mercapt~-2-propanol (II) (11.3 g).
Yield, 37 %. M.P., 156 - 157C. [~]D4 ~7 0 (c = 1, methanol).
Example 4 - l l -Preparation of (R)-3-(n-butylthio)--2-(2,4-di-chlorophenyl)-l-(imidazol l-yl)-2-propanol (I: n = 3) hydrochloride:-To a solution of sodium hydro~ide (2 ~) inmethanol (100 ml) were added n-butylbromide (2 g) and (~)-2-(2,4-dichlorophenyl)-1-(imidazol-1-yl)-3-mercapto-2-propanol (II) obtained in Example 2 at a temperature of 20 - 25C in nitrogen atmosphere. The mixture was stirred at 25 - 30C
for 5 hours and then concentrated under reduced pressure.
The residue was treated with water (50 ml) and extracted with dichloromethane (50 ml). The extract was washed with water, dried over anhydrous magnesium sulfate and concen-trated to give an oil. The oil was dissolved in diethyl ether (20 ml), and hydrogen chloride gas was introduced thereto. Precipitated crystals were collected by filtration and dried to give (R)-3-(n-butylthio)-2~(2,4-dichloro-phenyl)-1-(imidazol-1-yl)-2-propanol (I: n = 3) hydro-chloride (3.4 g). Yield, 86.8 %. M.P., 168 - 169C. [~]20 -89.7 (c = 1, methanol). The optical purity of the product was not less than 99 % determined by high performance liquid chromatography.
Example 5 Preparation of ~R)-3-(n-butylthio)-2-(2,4-di-chlorophenyl) l-(imida~ol-l-yl)-2-propanol (I: n = 3) hydrochloride:-T~ a solution of (R)-2-(2,4-dichlorophenyl)-1-limidazol-l-yl)-3-mercapto-2-propanol (II) t3 g) in dxy N,N-dimeth~lformamide (20 ml) were added a 50 ~ dispersion of sodium hydride iII paraffin (1 g) and n-butyl p-toluene-sulfonate (2.3 g) at 0 - 5C in nitroclen atmosphere. The rnixture was stirred at 0 - 5C for 1 hour and at 20 - 25C
for 18 hours. The reactlon mixture was diluted wi-th water (200 ml) and extracted with dichloromethane. Treatment of the extract in the same manner as in Example 4 gave (R)-
3-(n-butylthio)-2-(2,4-dichlorophenyl)-1-(imidazol-l-yl)-2-propanol (I: n = 3) hydrochloride (2.5 g). Yield, 63.8 ~. M.P., 168 - 169C. [~]20 -88.8 ~c = l, methanol).
E~ample 6 Preparation of (R)-3-(n-butylthio)-2-(2,4-di-chlorophenyl)-l-~imidazol-l-yl)-2-propanol (I: n = 3) hydrochloride:-To a suspension of (R)-3-[(S)-2-(4-chlorophenyl)-isovalerylthio]-2-(2,4 dichlorophenyl)-1-(imidazol-1-yl)-2-propanol (VIb) (49.5 g) obtained in Example 1 in methanol (S00 ml) were added a 10 r~ methanolic potassium hydroxide solution (240 g) and n-butylbromide (21.6 g) at -5 to 0C in nitrogen atmosphere. The slurry was stirred at the same temperature for 2 hours and then at 30C for 3 hours.
Methanol was removed by distillation under atmospheric pressure, and the residue was treated with water (200 ml~
and extracted with 1,2-dichloroethane (200 ml). The extract was washed successively with water and 12 ~ hydrochloric acid (200 ml) and concentrated in vacuo. To the residue were added toluene (100 ml) and methyl ethyl ketone (35 ml), and the slurry was stirred at 15C for 3 hours. Filtration and drying in vacuo gave a crude product (25.7 g), which was recrystallized from methyl ethyl ~etone to give (R)-3-(n-butylthio)-2-(2,4-dichlorophenyl) 1-(imidazol-1-yl)-2-propanol (I: n = 3) hydrochloride (21.8 g) as colorless needle.s. Yield, 55 %. M.P., 168.5 - 170C. [~]20 -S9.8 (c = 1, methanol).
Reference Exa~ple 1 Preparation of (S)-2-(4-chlorophenyl)thioloiso-valeric acid (V):-To a solution of potassium hydroxide (296 g) inmethanol (1500 ml) was introduced hydrogen sulfide gas (180 g) from a gas-inlet tube at a temperature below 30C, and the mixture was cooled at -5C. A solution of (S)-2-(4-chlorophenyl)isovaleryl chloride (510 g) in toluene (1000 ml) was dropwise added thereto at a temperature of -5 to 10C. The mixture was stirred at the same temperature for 30 minutes, followed by addition of water ~2000 ml). A 35 %
hydrochloric acid (455 g) was dropwise added thereto. The toluene layer was washed with water ~500 ml) and concen-trated in vacuo to give (S)-2-(4-chlorophenyl)thioloiso-valeric acid (V) (504 g), which was used for the Eeaction in Example 1 without purification.
The optically active imidazolylpropanols (I) exhibit a remarkable antimicrobial activity against various microorsanisms, particularly fungi. Also, some of them show an antifungal activity against phytopathogenic fungi.
5~
A~vantageously, the optically active imidazolyl-propanol compounds (I) are quite low in toxicity, and their LD50 values are more than 500 mg/lcg when de-termined by oral route to mice. Thus, they are useful as antiEungal agents.
The optically active imidazolylpropanol compounds (I) can be administered parenterally, orally or locally to warm-blooded animals and human beings in the form of conventional pharmaceutical preparations. For instance, they can be administred in the form of conventional solid pharmaceutical preparations such as tablets, capsules, powders or granules, or in the form of conventional liquid pharmaceutical preparations such as suspensions, emulsions or solutions. The daily dosage may vary depending upon the administratlon route and is usually between 10 mg and 5 g for human beings.
E~ample 6 Preparation of (R)-3-(n-butylthio)-2-(2,4-di-chlorophenyl)-l-~imidazol-l-yl)-2-propanol (I: n = 3) hydrochloride:-To a suspension of (R)-3-[(S)-2-(4-chlorophenyl)-isovalerylthio]-2-(2,4 dichlorophenyl)-1-(imidazol-1-yl)-2-propanol (VIb) (49.5 g) obtained in Example 1 in methanol (S00 ml) were added a 10 r~ methanolic potassium hydroxide solution (240 g) and n-butylbromide (21.6 g) at -5 to 0C in nitrogen atmosphere. The slurry was stirred at the same temperature for 2 hours and then at 30C for 3 hours.
Methanol was removed by distillation under atmospheric pressure, and the residue was treated with water (200 ml~
and extracted with 1,2-dichloroethane (200 ml). The extract was washed successively with water and 12 ~ hydrochloric acid (200 ml) and concentrated in vacuo. To the residue were added toluene (100 ml) and methyl ethyl ketone (35 ml), and the slurry was stirred at 15C for 3 hours. Filtration and drying in vacuo gave a crude product (25.7 g), which was recrystallized from methyl ethyl ~etone to give (R)-3-(n-butylthio)-2-(2,4-dichlorophenyl) 1-(imidazol-1-yl)-2-propanol (I: n = 3) hydrochloride (21.8 g) as colorless needle.s. Yield, 55 %. M.P., 168.5 - 170C. [~]20 -S9.8 (c = 1, methanol).
Reference Exa~ple 1 Preparation of (S)-2-(4-chlorophenyl)thioloiso-valeric acid (V):-To a solution of potassium hydroxide (296 g) inmethanol (1500 ml) was introduced hydrogen sulfide gas (180 g) from a gas-inlet tube at a temperature below 30C, and the mixture was cooled at -5C. A solution of (S)-2-(4-chlorophenyl)isovaleryl chloride (510 g) in toluene (1000 ml) was dropwise added thereto at a temperature of -5 to 10C. The mixture was stirred at the same temperature for 30 minutes, followed by addition of water ~2000 ml). A 35 %
hydrochloric acid (455 g) was dropwise added thereto. The toluene layer was washed with water ~500 ml) and concen-trated in vacuo to give (S)-2-(4-chlorophenyl)thioloiso-valeric acid (V) (504 g), which was used for the Eeaction in Example 1 without purification.
The optically active imidazolylpropanols (I) exhibit a remarkable antimicrobial activity against various microorsanisms, particularly fungi. Also, some of them show an antifungal activity against phytopathogenic fungi.
5~
A~vantageously, the optically active imidazolyl-propanol compounds (I) are quite low in toxicity, and their LD50 values are more than 500 mg/lcg when de-termined by oral route to mice. Thus, they are useful as antiEungal agents.
The optically active imidazolylpropanol compounds (I) can be administered parenterally, orally or locally to warm-blooded animals and human beings in the form of conventional pharmaceutical preparations. For instance, they can be administred in the form of conventional solid pharmaceutical preparations such as tablets, capsules, powders or granules, or in the form of conventional liquid pharmaceutical preparations such as suspensions, emulsions or solutions. The daily dosage may vary depending upon the administratlon route and is usually between 10 mg and 5 g for human beings.
Claims (4)
1. A process for preparing optically active imidazolylpropanol compounds of the formula:
(I) wherein n is an integer of 3 or 4, and their acid addition salts, which comprises reacting an imidazolylthiol of the formula:
(II) with an alkylating agent of the formula:
CH3-(CH2)n-X (III) whrein n is as defined above and X is a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group.
(I) wherein n is an integer of 3 or 4, and their acid addition salts, which comprises reacting an imidazolylthiol of the formula:
(II) with an alkylating agent of the formula:
CH3-(CH2)n-X (III) whrein n is as defined above and X is a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group.
2. The process according to claim 1, wherein the reaction is carried out in the presence of a base.
3. A process for preparing optically active imidazolylpropanol compounds of the formula:
(I) wherein n is an integer of 3 or 4, and their acid addition salts, which comprises:
(1) reacting a racemic epoxide of the formula:
(IV) with an optically active thiolocarboxylic acid of the formula: A-SH wherein A is an optically active acyl group to give a mixture of two diastereomeric isomers of the formulas:
and (VIa) (VIb) wherein A is as defined above;
(2) separating the (R)-isomer from said mixture;
(3) reacting the (R)-isomer with a base to give an imidazolylthiol of the formula:
(II) and (4) reacting the imidazolylthiol with an alkylating agent of the formula:
CH3-(CH2)n-X (III) wherein n is as defined above and X is a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group.
(I) wherein n is an integer of 3 or 4, and their acid addition salts, which comprises:
(1) reacting a racemic epoxide of the formula:
(IV) with an optically active thiolocarboxylic acid of the formula: A-SH wherein A is an optically active acyl group to give a mixture of two diastereomeric isomers of the formulas:
and (VIa) (VIb) wherein A is as defined above;
(2) separating the (R)-isomer from said mixture;
(3) reacting the (R)-isomer with a base to give an imidazolylthiol of the formula:
(II) and (4) reacting the imidazolylthiol with an alkylating agent of the formula:
CH3-(CH2)n-X (III) wherein n is as defined above and X is a halogen atom, an alkylsulfonyloxy group or an arylsulfonyloxy group.
4. The process according to claim 3, wherein the optically active thiolocarboxylic acid is a compound of the formula:
(V)
(V)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000428760A CA1191856A (en) | 1983-05-24 | 1983-05-24 | Process for preparing optically active imidazolylpropanol compounds, and intermediate therein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA000428760A CA1191856A (en) | 1983-05-24 | 1983-05-24 | Process for preparing optically active imidazolylpropanol compounds, and intermediate therein |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1191856A true CA1191856A (en) | 1985-08-13 |
Family
ID=4125313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000428760A Expired CA1191856A (en) | 1983-05-24 | 1983-05-24 | Process for preparing optically active imidazolylpropanol compounds, and intermediate therein |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA1191856A (en) |
-
1983
- 1983-05-24 CA CA000428760A patent/CA1191856A/en not_active Expired
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200607092B (en) | Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as Faah enzyme inhibitors | |
KR890000377B1 (en) | Process for preparation azloes | |
US10584100B2 (en) | Solid state forms of netarsudil mesylate | |
EA015801B1 (en) | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | |
WO1997037982A1 (en) | Novel substituted [2-(1-piperazinyl)ethoxy]methyl | |
US4863941A (en) | Glycerol derivatives | |
CA2474627C (en) | R-(-)-1-[2-(7-chlorobenzo[b]thiophen-3-yl-methoxy)-2-(2,4-dichlorophenyl)-ethyl]-1h-imidazole | |
CA1325212C (en) | (benzofuran-2-yl) imidazoles having pharmaceutical activity, their salts and relevant production processes | |
US20010031778A1 (en) | Triazole antifungal agent | |
KR920002295B1 (en) | Process for the preparation of pyrrolidone derivatives | |
CA1191856A (en) | Process for preparing optically active imidazolylpropanol compounds, and intermediate therein | |
US4526983A (en) | Process for preparing optically active imidazolylpropanol compounds, and intermediate therein | |
EP0098942B1 (en) | Optically active imidazolylpropanol compounds, and their production and use | |
US5663365A (en) | Process for the preparation of pyrazolones | |
US4727156A (en) | 3-(Substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-{[(substituted phenyl)thio]me}isoxazolidine derivatives | |
US4777263A (en) | 5-substituted-3-(2-naphthalenyl)-3-((1H-imidazol-1-ylmethyl) or (1H-1,2,4-triazol-1-ylmethyl))-2-methylisoxazolidines | |
JPH0528708B2 (en) | ||
CA2247390A1 (en) | Azole compounds endowed with antimycotic activity for human and veterinary use | |
US6706888B2 (en) | Processes for preparing imidazole derivatives and salts thereof | |
US4777264A (en) | 5-carbonyl derivatives of 3-phenyl-3-(1H-imadazol-1-ylmethyl)-2-methylisoxazolidines and related compounds thereof | |
US4754042A (en) | 5-{[naphthyl(or 2-oxo-1,3-benzoxathiol-6-yl)oxy]methyl}-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | |
US4767866A (en) | 3-Phenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2-methyl-5-alkylisoxazolidines | |
US4767867A (en) | 5-(alkoxyalkyl)-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | |
KR101709543B1 (en) | Novel voriconazole intermediate and synthesis of voriconazole | |
FR2499569A1 (en) | NOVEL DERIVATIVES OF 1-BENZYL-4- (4- (2-PYRIMIDINYLAMINO) BENZYL) -2,3-DIOXOPIPERAZINES, THEIR SALTS, A PROCESS FOR PREPARING THESE DERIVATIVES AND SALTS AND A CARCINOSTATIC AGENT CONTAINING SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEC | Expiry (correction) | ||
MKEX | Expiry |